argenx SE

US · ARGX #369 by market cap Listed 2017

928.44 -2.08 -0.22%

Live - 5344 symbols - heartbeat 29s ago · 2026-10-08 07:00

Pre-market 793.55 -14.53%

After-hours 928.44 0.00%

Overnight 780.55 -15.93%

Market cap: 58.39B
P/E (TTM): 35.37
P/B: 6.94
EPS: 19.57
Div yield: 0.00%
52W pos: 65%

Reader sentiment Are you bullish or bearish on ARGX?

Anonymous reader poll. Unscientific, not investment advice.

About argenx SE

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Founded: 2008
CEO: Mr. Tim Van Hauwermeiren, M. Sc.
Employees: 3,522
Headquarters: Amsterdam, Noord-Holland, Netherlands (the)
Fiscal year end: 12-31
Website: argen-x.com

Company profile

Exchange: US
Symbol: ARGX
Market-cap rank: #369
Listing date: 2017-05-18
Market cap: 58.39B
Float cap: 58.29B
Shares out: 62.89M
Float shares: 62.78M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:18 · For reference only, not investment advice and not tailored to your situation.